BG-68501-101: A PHASE 1A/1B STUDY OF BG-68501, A SELECTIVE CDK2 INHIBITOR, IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Objective

Clinical Trial Details

Principal Investigator(s)
David Starks, MD

Clinical Trial Categories

  • Cancer
  • Breast Cancer
  • Gynecologic Cancer
Contact
Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org

Location

  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000